A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

29 citing papers in PubMed.

1. A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.Cancer science · 2020
   Trial
2. Comprehensive analysis of metabolic pathway activity subtypes derived prognostic signature in hepatocellular carcinoma.Cancer medicine · 2023
   Article
3. Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities.Cancers · 2022
   Review
4. Genetic Landscape of Multistep Hepatocarcinogenesis.Cancers · 2022
   Review
5. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook.Journal of hepatocellular carcinoma · 2022
   Review
6. Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study.Journal of clinical medicine · 2021
   Article
7. Altered Protein and Gene Expression of Beclin-1 Correlates with Poor Prognosis of Hcv-Associated Hepatocellular Carcinoma in Egyptian Patients.Asian Pacific journal of cancer prevention : APJCP · 2021
   Article
8. Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance.Journal of controlled release : official journal of the Controlled Release Society · 2021
   Article
9. Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway.BioMed research international · 2021
   Article
10. Therapy in Advanced Hepatocellular Carcinoma.Seminars in interventional radiology · 2020
    Review
11. TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma.Molecular medicine reports · 2020
    Article
12. Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2020
    Article
13. Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion.Molecular and clinical oncology · 2019
    Article
14. Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients.Liver cancer · 2019
    Review
15. Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan.Liver cancer · 2019
    Article
16. Liver damage related to immune checkpoint inhibitors.Hepatology international · 2019
    Review
17. Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion.Hepatology research : the official journal of the Japan Society of Hepatology · 2019
    Article
18. Cabozantinib for advanced hepatocellular carcinoma.Hepatobiliary surgery and nutrition · 2019
    Article
19. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.World journal of gastroenterology · 2019
    Review
20. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.The oncologist · 2019
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.